{"document": {"publication": "Tag My News", "full_text": "a second pivotal trial of ruxolitinib, developed by incyte corp and novartis, met its goal of showing that the drug significantly reduces spleen size in myelofibrosis patients.", "title": "incyte, novartis myelofibrosis trial meets goal", "line_count": 1, "filename": "33640", "publication_date": "04-06-2011 20:30:36", "lines_and_colors": [["a second pivotal trial of ruxolitinib, developed by incyte corp and novartis, met its goal of showing that the drug significantly reduces spleen size in myelofibrosis patients.", {}]]}}